Asia
InnoCare Pharma's Phase III Trial of Fadeucravacitinib Meets Primary Endpoint
InnoCare Pharma (HKG:9969, SHA:688428) said the Phase III clinical trial of fadeucravacitinib met its primary endpoint, according to a Hong Kong bourse disclosure on Monday.The pharmaceutical company's Hong Kong shares rose 1% during Tuesday's midday trade.The drug was tested as a treatment for patients with moderate-to-severe plaque psoriasis.The drug's safety profile was consistent with previous clinical studies and no new safety signals were identified. Results from the study will be presented at upcoming international scientific congresses and in medical journals.
HKG:9969SHA:688428